Xenetic Biosciences Inc. (XBIO)
XBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1534525/000168316826001737/0001683168-26-001737-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001534525 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.0M |
| Net income | -$2.7M |
| Operating income | -$2.8M |
| Net margin | -90.1% |
| Operating margin | -95.2% |
| Revenue growth | +19.0% |
| Cash | $7.9M |
| Total assets | $8.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Going Concern and Management's Plan Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $5.8M cash; operating cash flow -$579K a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,343,181 (2026-11-06); 2,291,056 a year earlier; 1,540,684 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $725K | -$1.7M | -$662K | $5.8M | No debt tags | $3.0M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $661K | -$930K | -$875K | $6.5M | No debt tags | $3.3M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $807K | -$456K | -$536K | $7.3M | No debt tags | $3.2M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $766K | -$579K | -$243K | $7.9M | No debt tags | $3.0M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $1.0M | -$510K | -$658K | $4.1M | No debt tags | $2.9M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $590K | -$689K | -$384K | $4.8M | No debt tags | $2.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $593K | -$903K | -$1.0M | $5.2M | No debt tags | $2.6M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $649K | -$1.1M | -$674K | $6.2M | No debt tags | $2.5M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2025-10-14 |
| Latest annual report FORM 10-K FOR DEC 2025 AMENDMENT 1 | 10-K/A | 2026-04-24 |
| Latest quarterly / interim FORM 10-Q FOR SEP 2026 | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-11-13 |
Source: SEC EDGAR submissions feed, 488 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.3% |
| 1 month | -21.0% |
| 3 months | -49.5% |
| Year to date | -23.5% |
| 1 year | -35.4% |
| From 52-week high | -64.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.54 | -3.75% | $3.8M |
| AZTR | Azitra Inc | $0.6270 | +3.06% | $3.8M |
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| GELS | Gelteq Limited | $0.3589 | -5.63% | $3.8M |
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier